Global Blood Therapeutics Company Profile (NASDAQ:GBT)

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics logoGlobal Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GBT
  • CUSIP: N/A
  • Web: www.globalbloodtx.com
Capitalization:
  • Market Cap: $1.21681 billion
  • Outstanding Shares: 43,613,000
Average Prices:
  • 50 Day Moving Avg: $28.55
  • 200 Day Moving Avg: $27.97
  • 52 Week Range: $13.35 - $41.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $7.03 per share
  • Price / Book: 3.84
Profitability:
  • EBIDTA: ($88,620,000.00)
  • Return on Equity: -38.73%
  • Return on Assets: -36.38%
Debt:
  • Current Ratio: 16.85%
  • Quick Ratio: 16.85%
Misc:
  • Average Volume: 784,986 shs.
  • Beta: 4.36
  • Short Ratio: 5.59
 
Frequently Asked Questions for Global Blood Therapeutics (NASDAQ:GBT)

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its quarterly earnings results on Monday, May, 1st. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.11. During the same quarter last year, the business posted ($0.56) earnings per share. View Global Blood Therapeutics' Earnings History.

Where is Global Blood Therapeutics' stock going? Where will Global Blood Therapeutics' stock price be in 2017?

11 equities research analysts have issued twelve-month price objectives for Global Blood Therapeutics' shares. Their predictions range from $23.05 to $83.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $53.61 in the next year. View Analyst Ratings for Global Blood Therapeutics.

What are analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:

  • 1. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/16/2017)
  • 3. Cantor Fitzgerald analysts commented, "We are initiating coverage on Global Blood Therapeutics (GBT) with an Overweight rating and a $61/share price target. We believe Global Blood's lead candidate, GBT440, has demonstrated compelling potential for the treatment of sickle cell disease (SCD), based on its reported clinical efficacy and safety data. Moreover, we believe the mechanism of action of oxygen affinity modulation is strongly validated in the scientific literature. Sickle cell disease remains a therapeutic area with a significant unmet need, for which the only approved therapy demonstrating clinical benefit is carcinogenic. Global Blood is currently enrolling up to 400 patients with SCD in its Phase 3 study." (3/15/2017)
  • 4. J P Morgan Chase & Co analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)
  • 5. Instinet analysts commented, "We are initiating coverage of GBT with a Buy rating and $50 price target. We view GBT shares as attractively valued following selloffs in 2016 and expect additional data in 2017 to yield upside by providing further clarity on GBT440's safety and efficacy profile. Specifically, we anticipate upside to GBT shares following a positive readout from the biomarker-driven Phase 2 trials of GBT440 in patients with IPF in 2H17. We expect renewed interest in this readout and the timing of this readout to alleviate the perception that shares are 'dead money' between now and GBT's final Phase 3 read-out in SCD in 1H19. We believe that data from IPF together with updates from the extension studies in SCD will further support GBT440's mechanism of action, better framing the risk around the primary share driver, Phase 3 readout in SCD. The opportunity for IPF remains $16 per share upside to our $50 target price." (3/1/2017)

Are investors shorting Global Blood Therapeutics?

Global Blood Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totalling 5,907,109 shares, an increase of 48.5% from the June 15th total of 3,976,776 shares. Based on an average daily volume of 1,530,712 shares, the days-to-cover ratio is currently 3.9 days. Approximately 15.2% of the company's shares are sold short.

Who are some of Global Blood Therapeutics' key competitors?

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:

  • Ted W. Love M.D., President, Chief Executive Officer, Director
  • Jeffrey S. Farrow, Chief Financial Officer
  • Peter Radovich, Senior Vice President, Operations
  • Hing L. Sham, Senior Vice President, Research
  • Jung E. Choi, Chief Business and Strategy Officer
  • Tricia Borga Suvari Esq., Chief Legal Officer
  • Charles J. Homcy M.D., Director
  • Willie L. Brown Jr, Independent Director
  • Scott W. Morrison, Independent Director
  • Deval L. Patrick, Independent Director

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who owns Global Blood Therapeutics stock?

Global Blood Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Hamilton Lane Advisors LLC (0.25%), Bessemer Group Inc. (0.11%), Russell Investments Group Ltd. (0.10%), Creative Planning (0.10%), Hershey Trust Co. (0.10%) and ING Groep NV (0.06%). Company insiders that own Global Blood Therapeutics stock include Deval L Patrick, Eleanor Ramos, John Schembri, Jung Choi, Kevin P Starr and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.

Who sold Global Blood Therapeutics stock? Who is selling Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including ING Groep NV, Nisa Investment Advisors LLC and Bank of Montreal Can. Company insiders that have sold Global Blood Therapeutics stock in the last year include Deval L Patrick, Jung Choi, Kevin P Starr and Robert I Tepper. View Insider Buying and Selling for Global Blood Therapeutics.

Who bought Global Blood Therapeutics stock? Who is buying Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC, Bessemer Group Inc., Hershey Trust Co., Creative Planning, Spark Investment Management LLC, Parametrica Management Ltd and Russell Investments Group Ltd.. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eleanor Ramos and John Schembri. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy Global Blood Therapeutics stock?

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of Global Blood Therapeutics stock can currently be purchased for approximately $27.00.


MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Global Blood Therapeutics (NASDAQ:GBT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $53.61 (98.54% upside)

Analysts' Ratings History for Global Blood Therapeutics (NASDAQ:GBT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/11/2017Morgan StanleyReiterated RatingOverweightLowView Rating Details
5/2/2017WedbushReiterated RatingOutperform$73.00HighView Rating Details
5/1/2017Janney Montgomery ScottInitiated CoverageBuy$37.00LowView Rating Details
4/17/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$56.00HighView Rating Details
3/20/2017Roth CapitalSet Price TargetBuy$47.00LowView Rating Details
3/15/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$61.00LowView Rating Details
3/15/2017J P Morgan Chase & CoReiterated RatingBuy$44.00MediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$50.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/5/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
9/30/2016Wells Fargo & CompanyInitiated CoverageOutperform$75.00 -> $23.05N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$43.00 -> $26.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Global Blood Therapeutics (NASDAQ:GBT)
Earnings by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Earnings History by Quarter for Global Blood Therapeutics (NASDAQ GBT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($0.71)($0.60)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.64)($0.74)ViewN/AView Earnings Details
11/9/2016Q316($0.58)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.63)($0.58)ViewN/AView Earnings Details
5/12/2016Q1($0.48)($0.56)ViewN/AView Earnings Details
3/29/2016Q4($0.64)($0.53)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.71)($0.90)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Global Blood Therapeutics (NASDAQ:GBT)
Current Year EPS Consensus Estimate: $-2.51 EPS
Next Year EPS Consensus Estimate: $-2.93 EPS

Dividends

Dividend History for Global Blood Therapeutics (NASDAQ:GBT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Global Blood Therapeutics (NASDAQ:GBT)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 71.72%
Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Deval L PatrickDirectorSell27,053$29.69$803,203.57View SEC Filing  
7/21/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
4/6/2017Robert I TepperMajor ShareholderSell31,225$33.23$1,037,606.75View SEC Filing  
12/16/2016Kevin P StarrMajor ShareholderSell108,955$16.00$1,743,280.00View SEC Filing  
1/7/2016John SchembriinsiderBuy1,500$21.57$32,355.00View SEC Filing  
12/22/2015Eleanor RamosinsiderBuy11,000$20.93$230,230.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Global Blood Therapeutics (NASDAQ:GBT)
Latest Headlines for Global Blood Therapeutics (NASDAQ:GBT)
Source:
DateHeadline
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Director Sells $803,203.57 in Stock
www.americanbankingnews.com - July 27 at 7:42 PM
globenewswire.com logoGlobal Blood Therapeutics Announces New Employment Inducement Grants - GlobeNewswire (press release)
globenewswire.com - July 27 at 12:32 AM
nasdaq.com logoGlobal Blood Therapeutics Announces New Employment Inducement Grants - Nasdaq
www.nasdaq.com - July 26 at 7:32 PM
finance.yahoo.com logoGlobal Blood Therapeutics Announces New Employment Inducement Grants
finance.yahoo.com - July 26 at 7:32 PM
americanbankingnews.com logoInsider Selling: Global Blood Therapeutics, Inc. (GBT) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - July 25 at 7:51 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - July 23 at 5:34 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 6:51 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Short Interest Up 48.5% in June
www.americanbankingnews.com - July 15 at 7:22 AM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Expected to Announce Earnings of -$0.60 Per Share
www.americanbankingnews.com - July 12 at 10:18 AM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Earns Overweight Rating from Morgan Stanley
www.americanbankingnews.com - July 11 at 7:08 AM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Expands Phase 2a HOPE-KIDS 1 Study into Younger Pediatric - StreetInsider.com
www.streetinsider.com - July 10 at 6:53 PM
finance.yahoo.com logoGlobal Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population
finance.yahoo.com - July 10 at 6:53 PM
seekingalpha.com logoGlobal Blood Therapeutics Continues To Be An Attractive Run-Up Play
seekingalpha.com - July 6 at 8:15 PM
finance.yahoo.com logoImplied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
finance.yahoo.com - July 3 at 6:38 PM
thestreet.com logoGlobal Blood Shares Pop on Priority Designation; Kite Pharma ... - TheStreet.com
www.thestreet.com - June 29 at 4:41 AM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Receives EMA PRIME ... - StreetInsider.com
www.streetinsider.com - June 29 at 4:41 AM
marketwatch.com logoGlobal Blood Therapeutics stock surges 5% on eligibility for ... - MarketWatch
www.marketwatch.com - June 29 at 4:41 AM
finance.yahoo.com logoGlobal Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)
finance.yahoo.com - June 28 at 6:31 PM
finance.yahoo.com logoGlobal Blood Therapeutics stock surges 5% on eligibility for European priority drug program
finance.yahoo.com - June 28 at 6:31 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 26 at 6:49 PM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Reports New Data Supporting Ongoing Clinical Development of GBT440 in ... - StreetInsider.com
www.streetinsider.com - June 24 at 1:33 AM
finance.yahoo.com logoGlobal Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease
finance.yahoo.com - June 23 at 3:22 PM
nasdaq.com logoGlobal Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents ... - Nasdaq
www.nasdaq.com - June 23 at 4:37 AM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - June 20 at 7:20 PM
nasdaq.com logoNotable Tuesday Option Activity: GBT, GOOG, LQ
www.nasdaq.com - June 20 at 6:07 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Expected to Post Earnings of -$0.60 Per Share
www.americanbankingnews.com - June 16 at 10:22 AM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - June 10 at 11:44 PM
globenewswire.com logoGlobal Blood Therapeutics Announces Participation at the Goldman ... - GlobeNewswire (press release)
globenewswire.com - June 6 at 10:47 PM
finance.yahoo.com logoGlobal Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 6 at 5:47 PM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Cut to Sell at ValuEngine
www.americanbankingnews.com - June 3 at 3:50 PM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 30 at 6:36 PM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell ... - StreetInsider.com
www.streetinsider.com - May 20 at 5:16 PM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at EHA
www.streetinsider.com - May 19 at 9:31 AM
finance.yahoo.com logoGlobal Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress
finance.yahoo.com - May 19 at 9:31 AM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 5 at 10:50 AM
americanbankingnews.com logoGlobal Blood Therapeutics (GBT) Earns News Impact Score of 0.08
www.americanbankingnews.com - May 4 at 10:11 AM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Rating Reiterated by Wedbush
www.americanbankingnews.com - May 2 at 10:18 AM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS
www.americanbankingnews.com - May 1 at 11:36 PM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Coverage Initiated at Janney Montgomery Scott
www.americanbankingnews.com - May 1 at 8:46 PM
americanbankingnews.com logoGlobal Blood Therapeutics (GBT) Given Daily Coverage Optimism Score of 0.10
www.americanbankingnews.com - May 1 at 5:42 PM
finance.yahoo.com logoGlobal Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results
finance.yahoo.com - May 1 at 5:09 PM
marketbeat.com logoGlobal Blood reports 1Q loss
marketbeat.com - May 1 at 4:12 PM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Expected to Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 28 at 11:36 AM
americanbankingnews.com logoGlobal Blood Therapeutics (GBT) Earns News Sentiment Rating of -0.20
www.americanbankingnews.com - April 28 at 11:30 AM
americanbankingnews.com logoGlobal Blood Therapeutics (GBT) Earning Somewhat Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 23 at 6:37 PM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Receives New Coverage from Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - April 17 at 9:51 PM
americanbankingnews.com logoGlobal Blood Therapeutics (GBT) Given Media Impact Score of -0.12
www.americanbankingnews.com - April 16 at 1:01 PM
americanbankingnews.com logoGlobal Blood Therapeutics (GBT) Getting Somewhat Negative Media Coverage, Study Finds
www.americanbankingnews.com - April 13 at 11:40 AM
americanbankingnews.com logoGlobal Blood Therapeutics Inc (GBT) Short Interest Update
www.americanbankingnews.com - April 11 at 7:15 AM
americanbankingnews.com logoInsider Selling: Global Blood Therapeutics Inc (GBT) Major Shareholder Sells 31,225 Shares of Stock
www.americanbankingnews.com - April 10 at 7:51 PM

Social

Chart

Global Blood Therapeutics (GBT) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff